Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first-in-human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1-3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1-180 mg) was carried out to assess dose-limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25-(OH) 2 -vitamin D)
| INTRODUC TI ON
Fibroblast growth factor receptors are a family of four highly conserved transmembrane receptor tyrosine kinases (FGFR1-4) that can bind FGF ligands.
1 FGF signaling is implicated in downstream transduction pathways that regulate several key cellular processes, including proliferation, differentiation, migration, and survival. 2 The signaling pathway is frequently perturbed in cancer, often manifesting as FGFR amplification and mutation, oncogenic fusion, dysregulated FGF ligand signaling, and promotion of angiogenesis. 3 Although anti-FGFR therapy represents a promising targeted cancer treatment, early phase clinical trials have had mixed success, with response to therapy dependent on several factors, including cancer type, tumor histology, and presence or absence of certain biomarkers. 4 Trials of non-selective, multi-target tyrosine kinase inhibitors have shown variable anti-FGFR activity and broad-spectrum off-target inhibition of other tyrosine kinases, notably vascular endothelial growth factor, leading to toxicities. 5 Off-target inhibition has also been associated with several other AE, such as bone marrow suppression caused by platelet-derived growth factor inhibition and skin rash caused by KIT inhibition. 6 Thus, selective inhibitors may offer the benefit of reduced toxicity by eliminating concerns about such off-target effects.
To date, several selective FGFR inhibitors have been assessed in early phase clinical testing. A phase I study of the selective FGFR1-3 inhibitor AZD4547 in patients with squamous cell lung cancers confirmed target inhibition but failed to achieve its efficacy endpoint.
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In Japanese patients with advanced solid tumors, AZD4547 was well tolerated, with best response being stable disease (duration ≥4 weeks). 8 BGJ398, another selective FGFR1-3 inhibitor, showed
antitumor activity in several tumor types and had a tolerable safety profile in a phase I study in patients with advanced solid tumors, 9 whereas JNJ-42756493, a pan-FGFR inhibitor recently approved by the FDA for urothelial carcinoma, 10 showed a clinical response with acceptable safety in a similar patient population. 11 Similar findings have been reported for the pan-FGFR inhibitors LY2874455 12 and ARQ 087. 13 Clinical trials are ongoing for other highly selective FGFR inhibitors in development, such as TAS-120 14 
| MATERIAL S AND ME THODS

| Patients
Patients aged ≥20 years with histologically or cytologically confirmed advanced solid tumors refractory to standard therapy, or for whom no appropriate treatment was available, were eligible for the study. Other inclusion criteria included corrected serum calcium and phosphate ≤ upper limit of normal and ECOG performance status of 0 or 1. Patients with brain metastasis associated with clinical symptoms or requiring treatment, current evidence or history of ≥ grade 2 corneal disorder, or a history of clinically significant cardiovascular impairment were excluded. Patients who had previously been treated with FGFR inhibitors were also excluded.
| Study design
This first-in-human phase I study conducted in Japan consisted of two parts: a single-center dose-escalation study to assess DLT and to determine MTD in patients with advanced solid tumors (Part 1), and a multicenter expansion part restricted to patients with tumors harboring FGFR alterations, including gastric cancer with FGFR2 amplification and cholangiocarcinoma with FGFR2 fusion (Part 2) ( Figure S1 ).
The current report describes results from Part 1; Part 2 of the study is ongoing and results will be described in a subsequent publication.
A mTPI design 18 was used to determine the MTD of E7090, with each cohort assigned a dose of E7090 in accordance with the rules of the mTPI design based on a target DLT rate of 25% ± 5% Adverse events were coded using the Medical Dictionary for Regulatory Activities v20.1, and severity grades were determined using the Common Terminology Criteria for Adverse Events v4.03.
| Safety and tolerability
| Efficacy
Tumor assessment by computed tomography and/or magnetic resonance imaging was carried out according to RECIST v1.1 guidelines
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at screening, once every 8 weeks from day 1 of cycle 1, and at study discontinuation.
| Pharmacokinetic analysis
Blood samples for PK analysis were obtained before dosing in all cycles and at specific time points after giving E7090 up to cycle 
| Pharmacodynamics, pharmacogenomics and biomarker assessments
Blood samples, stored tumor samples, and tumor biopsy samples were obtained before giving E7090 in cycle 0, cycle 1, subsequent odd-numbered cycles, and after dosing in cycle 0 for days 
| Statistical analyses
Descriptive statistics were used to analyze demographic and other baseline characteristics and safety assessments. All patients who received at least one dose of E7090 were included in the safety analysis.
These patients had one or more target lesions as defined by RECIST v1.1 and were included in the analysis of best overall response. Efficacy analysis set included patients in the safety analysis set who underwent tumor assessment at baseline and at least once post-baseline. Plasma concentrations of E7090 were analyzed using a non-compartmental analysis to determine PK parameters (maximum plasma concentration The number of patients required for inclusion in Part 1 of the study was estimated to be approximately 20, based on the recommended sample size to reach MTD using nine dose levels, each with a cohort size of two. 
| RE SULTS
| Patients
| Safety
No DLT was observed between 1 mg QD and 140 mg QD. Of the 24 patients treated, three experienced a SAE (dyspnea in one subject in the 8-mg QD cohort, tumor pain in one subject in the 8-mg QD cohort, and pyrexia in one subject in the 30-mg cohort). None of the SAE was considered to be related to the study drug (Table 2) .
No drug-related deaths were reported, and no TEAE led to discontinuation of the study drug. TEAE leading to dose reductions were increased ALT (n = 2), increased AST (n = 1), and PPE syndrome (n = 2). Reasons for TEAE-related dose interruptions included nausea (n = 3), vomiting (n = 2), anorexia (n = 2), nasopharyngitis (n = 1), and decreased neutrophil count (n = 1). Selective FGFR inhibition has been associated with an increased risk of hyperphosphatemia 20 and eye toxicity, including retinal detachment. 8, 13 In the present study, there were nine AE of hyperphosphatemia and three AE of retinal detachment, but all were <grade 3 in severity and did not lead to dose reduction or discontinuation.
The dose levels are shown in Figure S2 . One patient experienced a DLT (grade 3 increased AST/ALT) in the 180-mg cohort, whereas no DLT were reported at doses up to and including 140 mg. Because sufficient inhibition of the targeted signaling pathway was obtained at 100-140 mg (as shown by PD markers described in the later section) and the safety profile at this dose level was acceptable, the recommended dose for Part 2 was determined as 140 mg QD.
| Pharmacokinetics
Following both single and repeat oral administration, once-daily E7090
was cleared from plasma with a mean terminal elimination phase halflife (T 1/2 ) of 15-27 hours. Dose-dependent increases in C max and AUC (0-t) were observed up to 180 mg E7090 (Figure 1) . T max was similar among doses, with a median of 2-5 hours. Excretion of unchanged form into urine was low (data not shown). The PK parameters are presented in Table 3 and include data only from patients who received ≥30 mg E7090, as plasma concentrations in the 1-16-mg cohorts at 72 hours after dosing were below the limit of quantification. 
| Pharmacodynamics
| Antitumor activity
One patient achieved a partial response and seven patients achieved stable disease (Table S2) . Fourteen patients had a best overall response of progressive disease, and two patients were not evaluable. The patient (a 45-year-old woman) who showed a partial response was in the 180-mg cohort, had diffuse-type gastric cancer with para-aortic lymph 
TA B L E 1 Patient demographic and baseline characteristics
All patients N = 24 (%)
TA B L E 2 Treatment-related treatment-emergent adverse events (occurring in ≥10% of the total study population)
Preferred term 
| D ISCUSS I ON
In the present study, E7090 was evaluated as monotherapy at total whereas AZD4547 has also been shown to increase serum phosphate but not FGF23.
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The toxicity profile of E7090 was generally consistent with previous findings in non-clinical studies. In the present study, SAE occurred in three patients (although none was considered related Note: Data are shown as mean ± SD, except T max ; for T max , median (range) is shown.
Abbreviations: AUC, area under the concentration-time curve; C avg , average plasma concentration; CL/F, total clearance; C max , maximum plasma concentration; C min , minimum plasma concentration; T 1/2 , terminal elimination phase half-life; T max , time to reach maximum plasma concentration; Vz/F, volume of distribution. a n = 2; data are missing for one patient who discontinued treatment prior to cycle 1, day 22 because of progressive disease.
to the study drug), and no drug-related deaths or TEAE requiring discontinuation of the study drug were reported. For Part 2, phatemia, which appears to play a role in FGF23 signaling 20 and eye toxicity such as macular edema and retinal detachment, as reported previously. 8, 13 No clear relationship between these toxicities and the inhibition of FGFR has been found. Skin and eye toxicities are a concern as a class effect of FGFR inhibition 1 and although PPE syndrome and retinal detachment AE occurred in this study, they were <grade 3, manageable, and did not lead to dose discontinuation.
Similarly, in a phase I study of JNJ-42756493, detachment of retinal pigment epithelium <grade 3 was the only DLT observed, and occurred only at the highest dose investigated (12 mg). 21 However, in a phase I study of AZD4547, grade 3 central serous retinopathy was reported in two patients in a dose-escalation cohort.
With respect to efficacy, promising antitumor activity was observed in one gastric cancer patient with an FGFR2 amplification.
Although E7090 did not show potent antitumor activity in patients with cholangiocarcinoma with FGFR2 fusion in the 30-mg cohort, this could be attributable to insufficient dosing. In preclinical models of tumors harboring FGFR abnormalities, E7090 elicited a significantly prolonged survival effect in mice with tumors metastasized to the lung. 16 In a previous study of AZD4547, a selective with paclitaxel, although considerable intratumor heterogeneity was observed in the study population. 25 However, phase II data on the efficacy of JNJ-42756493 in patients with advanced urothelial cancer showing specific FGFR genetic alterations indicated promising outcomes, including a 32% objective response rate and median response duration of 5.4 months.
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A limitation of this first-in-human study was the small number of patients included, an inherent feature of early-phase trials. A notable feature of the present study was the use of a modified toxicity probability interval design, which has been shown to be a safer and more robust alternative to the standard 3 + 3 design for phase I dose-escalation oncology trials. 18 In conclusion, this first-in-human phase I study indicates that E7090 has an acceptable safety profile; dose-dependent PK pa- 
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